• Aptadir Therapeutics closed a seed financing round of EUR 40 million, billed as Italy’s largest biotech seed round.
• CDP Venture Capital participated via its Digital Transition Fund, alongside lead investor 4BIO Capital.
• Proceeds target development of RNA inhibitor therapeutics, led by CAP1-FMR1 for Fragile X Syndrome, ahead of clinical work.
• Aptadir develops DNMTs Interacting RNAs designed to reverse abnormal gene silencing implicated in cancers and genetic disorders.
• EXTEND, the Italian technology transfer hub initiated by CDP Venture Capital, also made a follow-on investment from its pre-seed stake.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cdp Venture Capital Sgr SpA published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.